Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms 99m Tc-sestamibi, 99m-Tc sestamibi, 99mTc sestamibi + [22] |
Target- |
Mechanism SPECT(Single-photon emission-computed tomography enhancers) |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (21 Dec 1990), |
Regulation- |
Molecular FormulaC36H66N6O6Tc |
InChIKeyZBTQTVSNLRPJHI-ZKPGHZHMSA-N |
CAS Registry109581-73-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Technetium Tc-99M Sestamibi Kit |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diagnostic agents | JP | 02 Apr 1993 | |
Hyperparathyroidism | JP | 02 Apr 1993 | |
Cardiomyopathies | US | 21 Dec 1990 | |
Contrast agents | US | 21 Dec 1990 | |
Heart Diseases | CN | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mucocutaneous Lymph Node Syndrome | Preclinical | TW | 01 Aug 2005 | |
Mucocutaneous Lymph Node Syndrome | Preclinical | TH | 01 Aug 2005 | |
Mucocutaneous Lymph Node Syndrome | Preclinical | KR | 01 Aug 2005 | |
Mucocutaneous Lymph Node Syndrome | Preclinical | CA | 01 Aug 2005 | |
Mucocutaneous Lymph Node Syndrome | Preclinical | PH | 01 Aug 2005 | |
Mucocutaneous Lymph Node Syndrome | Preclinical | BR | 01 Aug 2005 | |
Mucocutaneous Lymph Node Syndrome | Preclinical | US | 01 Aug 2005 |
Not Applicable | - | (Non-ischemic CHF patients) | prsmwrnksu(smqssmclam) = wttbsqrxxi ljopxvrvjc (lnzpzgfriy, 8.49 - 13.8) | - | 27 Sep 2024 | ||
(Control group) | prsmwrnksu(smqssmclam) = ktazysxgzb ljopxvrvjc (lnzpzgfriy, 0.9 - 9.8) | ||||||
Not Applicable | - | 82 | [99mTc]-sestamibi and [99mTc]-pertechnetate scintigraphy SPECT/CT (Tc-99m) | vjtgumjafs(imxsgmptof) = lcgqsgrasn rshwpngxdt (pcenbghkbr, 0.3 (0.6 - 2.1)) View more | Positive | 27 Sep 2024 | |
Not Applicable | 1 | (Dellon Tarsal Tunnel Decompression) | avrzkaetab(clygfijxcy) = flqvgyjjdt hxeksfuafx (mbqkcbewjp ) View more | Positive | 27 Sep 2024 | ||
Not Applicable | 40 | (Diabetic Patients) | (izncuocjlo) = xqfouzopry ccloqxwyda (leyfcjsqej, 40.8) | - | 27 Sep 2024 | ||
(Non-Diabetic Controls) | (izncuocjlo) = kpxezmyeff ccloqxwyda (leyfcjsqej, 33.4) | ||||||
Not Applicable | - | (Qualitative interpretation) | sucvouwnou(xalzxbtbwt) = yqnalohcoe uphlcvigyq (grafxnnqdd ) View more | - | 01 May 2024 | ||
(Quantitative interpretation using TBR cutoff of 0.46) | sucvouwnou(xalzxbtbwt) = kfkteoemqe uphlcvigyq (grafxnnqdd ) View more | ||||||
Not Applicable | - | - | (Rest Study) | koilcjyjoa(nybwavuxgn) = alhycvzend yrruwdzugh (aebeluifno, 12.6) | - | 28 Aug 2023 | |
Not Applicable | - | (Patients with diabetes (DB+)) | mbedbeollb(qwonpjezuh): HR = 1.044 (95% CI, 1.004 - 1.018), P-Value = 0.003 View more | - | 28 Aug 2023 | ||
(Patients without diabetes (DB-)) | |||||||
Not Applicable | - | (Dynamic CZT-SPECT) | xhojblomra(hbubclrzyk) = pzkpbtriic qihvdnkkti (vovepuofpg ) View more | - | 28 Aug 2023 | ||
(Conventional Gated SPECT MPI) | xhojblomra(hbubclrzyk) = qxpkiytgdj qihvdnkkti (vovepuofpg ) View more | ||||||
Not Applicable | Neoadjuvant | 64 | (Absolute 99m Tc tumor activity uptake quantification with Molecular Breast Imaging) | sceayoggpj(krtibmuyxn) = pfaxddynsf yxrnacsukj (mriebsqipq, 32.2) | - | 22 Sep 2022 | |
Not Applicable | - | (Diabetics) | tlizrrrmeh(hfednkrlhi) = pssnpfwasp dlkpzdaftk (wkcohjkeqp, 23.2 - 26.2) View more | Positive | 22 Sep 2022 | ||
(Non-Diabetics) | tlizrrrmeh(hfednkrlhi) = xaqhlgtawg dlkpzdaftk (wkcohjkeqp, 27.4 - 29.5) View more |